INTRODUCTION: Multiple sclerosis (MS) mainly affects women of fertile age. To date, the only recommendation for women with MS intending to become pregnant is to stop all treatment. This recommendation reflects the concerns about the effects of disease-modifying drugs (DMDs) on the offspring. The objective of the present study was to assess the potential long-term effects of maternal exposure to DMDs on the offspring. METHOD: This was a retrospective study revising medical data on the offspring of women with MS. These women now have children aged at least 1 year and include a group of patients that were not exposed to any DMDs for at least 3 months prior to pregnancy and during the whole gestation (control group). Another group of patients had at least 2 weeks of exposure to DMDs, mainly to interferon beta or glatiramer acetate RESULTS: The women with MS participating in this study have children currently aged, on average, 6.6 years (range 1-39 years). There was no pattern of drug-related adverse events or complications in the children whose mothers were exposed to DMDs. No specific long-term adverse events were observed in the offspring of women with MS who were exposed to drugs during pregnancy. The profile of relevant diagnoses in their children was similar to that of children whose mothers had not been exposed to DMDs. CONCLUSIONS: The present retrospective study did not show a specific profile of long-term deleterious drug effects on children born from mothers who were exposed to drugs for MS treatment.
INTRODUCTION:Multiple sclerosis (MS) mainly affects women of fertile age. To date, the only recommendation for women with MS intending to become pregnant is to stop all treatment. This recommendation reflects the concerns about the effects of disease-modifying drugs (DMDs) on the offspring. The objective of the present study was to assess the potential long-term effects of maternal exposure to DMDs on the offspring. METHOD: This was a retrospective study revising medical data on the offspring of women with MS. These women now have children aged at least 1 year and include a group of patients that were not exposed to any DMDs for at least 3 months prior to pregnancy and during the whole gestation (control group). Another group of patients had at least 2 weeks of exposure to DMDs, mainly to interferon beta or glatiramer acetate RESULTS: The women with MS participating in this study have children currently aged, on average, 6.6 years (range 1-39 years). There was no pattern of drug-related adverse events or complications in the children whose mothers were exposed to DMDs. No specific long-term adverse events were observed in the offspring of women with MS who were exposed to drugs during pregnancy. The profile of relevant diagnoses in their children was similar to that of children whose mothers had not been exposed to DMDs. CONCLUSIONS: The present retrospective study did not show a specific profile of long-term deleterious drug effects on children born from mothers who were exposed to drugs for MS treatment.
Authors: Tammie B Howard; Melissa S Tassinari; Karen B Feibus; Lisa L Mathis Journal: Am J Med Genet C Semin Med Genet Date: 2011-07-15 Impact factor: 3.908
Authors: Yara Dadalti Fragoso; Mike Boggild; Miguel Angel Macias-Islas; Adriana Carra; Kirsty Deborah Schaerer; Adriana Aguayo; Sandra Maria Garcia de Almeida; Marcos Papais Alvarenga; Regina Maria Papais Alvarenga; Soniza Vieira Alves-Leon; Walter Oleschko Arruda; Joseph Bruno Bidin Brooks; Elizabeth Regina Comini-Frota; Maria Lucia Brito Ferreira; Alessandro Finkelsztejn; Juliana Marcon Szymanski Finkelsztejn; Lucas Dias de Freitas; Andre Serafin Gallina; Paulo Diniz da Gama; Sergio Georgetto; Maria Cristina B Giacomo; Sidney Gomes; Marcus Vinicius Magno Gonçalves; Anderson Kuntz Grzesiuk; Damacio Ramon Kaimen-Maciel; Josiane Lopes; Giselle A Lourenco; Fabiola Rachid Malfetano; Nivea Macedo Oliveira Morales; Rogerio de Rizo Morales; Celso Luis Silva Oliveira; Patricia Onaha; Cristiane Patroclo; Sonia Beatriz Felix Ribeiro; Taysa Alexandrino Gonsalves Jube Ribeiro; Heidi Johanna Salminen; Patricia Santoro; Marcos Seefeld; Paula Vallegas Soares; Adriana Tarulla; Claudia Cristina Ferreira Vasconcelos Journal: Clin Neurol Neurosurg Date: 2012-05-26 Impact factor: 1.876
Authors: Yára D Fragoso; Alessandro Finkelsztejn; Damacio R Kaimen-Maciel; Anderson K Grzesiuk; Andre S Gallina; Josiane Lopes; Nivea M O Morales; Soniza V Alves-Leon; Sandra M G de Almeida Journal: CNS Drugs Date: 2010-11 Impact factor: 5.749